[{"from": "human", "value": "Provide a brief overview of this molecule. [C][C][Branch1][C][C][C][=C][Branch2][Ring1][Ring2][C][=C][Branch1][=Branch1][C][=C][Ring1][=Branch1][O][/C][=C][/C][=C][C][=C][C][=C][Ring1][=Branch1][O]"}, {"from": "gpt", "value": "The molecule is a novel, first-in-class, small-molecule AhR agonist that is indicated for the treatment of adult psoriasis. It is available as a topical cream to be applied to the affected area once daily. Tapiranof was first discovered as a metabolite (3,5-dihydroxy-4-isopropylstilbene) produced in Photorhabdus luminescens, a gram-negative bacillus that lives symbiotically with the Heterorhabditis nematodes. In 1959, it was noticed that Heterorhabditis with a high amount of 3,5-dihydroxy-4-isopropylstilbene did not putrefy once dead, thus suggesting its potential anti-inflammatory activity.   Tapinarof received initial approval from the FDA in 2022."}]